Systemic Therapy for Non-Serous Ovarian Carcinoma

Yanin Chávarri-Guerra; Eduardo González-Ochoa; Héctor De-la-Mora-Molina; Enrique Soto-Perez-de-Celis

Disclosures

Chin Clin Oncol. 2020;9(4):52 

In This Article

Conclusions

Non-serous EOC represent a heterogenous and uncommon group of tumors. Most of these are diagnosed in women in their fifties, present at earlier stages, and are less sensitive to conventional platinum-based chemotherapy regimens in comparison to high-grade serous tumors. In general, non-serous EOC have a better prognosis at early stages, with the exception being CCC and carcinosarcoma, which tend to be more aggressive and have less favorable survival rates. On the other hand, MOGCTs and sex-cord stromal tumors mainly affect young patients and have very good prognosis after adjuvant chemotherapy. Although these tumors are rare, understanding the available treatment options, as well as potential strategies to improve their management in the future, is essential for all clinicians providing care for women with ovarian cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....